GH Research (GHRS) Competitors $12.15 -0.91 (-6.97%) Closing price 08/6/2025 04:00 PM EasternExtended Trading$12.58 +0.43 (+3.52%) As of 07:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GHRS vs. MOR, KYMR, RARE, IMVT, ALVO, CRNX, MIRM, CPRX, GMTX, and OGNShould you be buying GH Research stock or one of its competitors? The main competitors of GH Research include MorphoSys (MOR), Kymera Therapeutics (KYMR), Ultragenyx Pharmaceutical (RARE), Immunovant (IMVT), Alvotech (ALVO), Crinetics Pharmaceuticals (CRNX), Mirum Pharmaceuticals (MIRM), Catalyst Pharmaceuticals (CPRX), Gemini Therapeutics (GMTX), and Organon & Co. (OGN). These companies are all part of the "pharmaceutical products" industry. GH Research vs. Its Competitors MorphoSys Kymera Therapeutics Ultragenyx Pharmaceutical Immunovant Alvotech Crinetics Pharmaceuticals Mirum Pharmaceuticals Catalyst Pharmaceuticals Gemini Therapeutics Organon & Co. MorphoSys (NASDAQ:MOR) and GH Research (NASDAQ:GHRS) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, media sentiment and dividends. Is MOR or GHRS more profitable? GH Research has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. GH Research's return on equity of -19.20% beat MorphoSys' return on equity.Company Net Margins Return on Equity Return on Assets MorphoSys-226.79% -694.31% -22.55% GH Research N/A -19.20%-18.40% Do insiders and institutionals hold more shares of MOR or GHRS? 18.4% of MorphoSys shares are owned by institutional investors. Comparatively, 56.9% of GH Research shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by company insiders. Comparatively, 41.6% of GH Research shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has stronger valuation & earnings, MOR or GHRS? GH Research has lower revenue, but higher earnings than MorphoSys. GH Research is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMorphoSys$238.28M11.99-$205.35M-$3.48-5.45GH ResearchN/AN/A-$38.96M-$0.79-15.38 Which has more volatility & risk, MOR or GHRS? MorphoSys has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Comparatively, GH Research has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500. Do analysts rate MOR or GHRS? GH Research has a consensus target price of $32.00, suggesting a potential upside of 163.37%. Given GH Research's stronger consensus rating and higher possible upside, analysts clearly believe GH Research is more favorable than MorphoSys.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00GH Research 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor MOR or GHRS? In the previous week, GH Research had 4 more articles in the media than MorphoSys. MarketBeat recorded 4 mentions for GH Research and 0 mentions for MorphoSys. GH Research's average media sentiment score of 1.14 beat MorphoSys' score of 0.00 indicating that GH Research is being referred to more favorably in the news media. Company Overall Sentiment MorphoSys Neutral GH Research Positive SummaryGH Research beats MorphoSys on 12 of the 15 factors compared between the two stocks. Get GH Research News Delivered to You Automatically Sign up to receive the latest news and ratings for GHRS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GHRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GHRS vs. The Competition Export to ExcelMetricGH ResearchMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$679.49M$3.01B$5.57B$9.47BDividend YieldN/A2.41%4.31%4.18%P/E Ratio-15.3816.5729.4123.99Price / SalesN/A316.60445.35187.89Price / CashN/A42.1735.8458.51Price / Book3.537.818.075.58Net Income-$38.96M-$54.52M$3.26B$265.35M7 Day Performance-15.39%0.41%0.45%-0.07%1 Month Performance-19.05%9.93%4.83%1.76%1 Year Performance13.66%15.18%30.22%25.39% GH Research Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GHRSGH Research2.7507 of 5 stars$12.15-7.0%$32.00+163.4%+9.0%$679.49MN/A-15.3810Positive NewsMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730KYMRKymera Therapeutics3.4848 of 5 stars$43.66+1.6%$59.11+35.4%-0.2%$2.80B$47.07M-14.08170Positive NewsRAREUltragenyx Pharmaceutical4.4967 of 5 stars$28.46+0.1%$83.08+191.9%-43.6%$2.69B$560.23M-4.841,294Trending NewsEarnings ReportAnalyst ForecastIMVTImmunovant1.5548 of 5 stars$16.09+2.4%$36.40+126.2%-42.7%$2.69BN/A-5.87120ALVOAlvotech3.1851 of 5 stars$8.87+0.9%$14.00+57.8%-23.9%$2.65B$491.98M23.971,032CRNXCrinetics Pharmaceuticals3.3579 of 5 stars$28.22+1.4%$69.50+146.3%-43.2%$2.61B$1.04M-7.39210MIRMMirum Pharmaceuticals3.377 of 5 stars$52.24+0.4%$65.50+25.4%+36.4%$2.58B$336.89M-32.45140News CoverageEarnings ReportCPRXCatalyst Pharmaceuticals4.8873 of 5 stars$21.73+2.9%$32.83+51.1%+34.6%$2.58B$491.73M13.8480Earnings ReportGMTXGemini TherapeuticsN/A$58.97-1.3%N/A+45.3%$2.56BN/A-58.9730News CoverageOGNOrganon & Co.4.843 of 5 stars$9.68-0.7%$18.00+86.0%-53.2%$2.53B$6.40B3.364,000Trending NewsEarnings ReportDividend AnnouncementHigh Trading Volume Related Companies and Tools Related Companies MorphoSys Alternatives Kymera Therapeutics Alternatives Ultragenyx Pharmaceutical Alternatives Immunovant Alternatives Alvotech Alternatives Crinetics Pharmaceuticals Alternatives Mirum Pharmaceuticals Alternatives Catalyst Pharmaceuticals Alternatives Gemini Therapeutics Alternatives Organon & Co. Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GHRS) was last updated on 8/7/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GH Research PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share GH Research With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
